SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000926617-22-000003
Filing Date
2022-01-05
Accepted
2022-01-05 12:33:53
Documents
14
Period of Report
2022-01-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20220105x8k.htm   iXBRL 8-K 74484
2 EX-99.1 awh-20220105xex99_1.htm EX-99.1 28563
3 GRAPHIC awh-20220105xex99_1g001.jpg GRAPHIC 135062
  Complete submission text file 0000926617-22-000003.txt   419707

Data Files

Seq Description Document Type Size
4 EX-101.SCH awh-20220105.xsd EX-101.SCH 2650
5 EX-101.LAB awh-20220105_lab.xml EX-101.LAB 15772
6 EX-101.PRE awh-20220105_pre.xml EX-101.PRE 11344
8 EXTRACTED XBRL INSTANCE DOCUMENT awh-20220105x8k_htm.xml XML 4972
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 22510216
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences